Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17107404rdf:typepubmed:Citationlld:pubmed
pubmed-article:17107404lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:17107404lifeskim:mentionsumls-concept:C0025202lld:lifeskim
pubmed-article:17107404lifeskim:mentionsumls-concept:C1881155lld:lifeskim
pubmed-article:17107404pubmed:issue6lld:pubmed
pubmed-article:17107404pubmed:dateCreated2006-11-19lld:pubmed
pubmed-article:17107404pubmed:abstractTextWe report a new immunological treatment for advanced cutaneous melanoma which combines laser stimulation with topical application of a toll-like receptor agonist. This treatment, in situ photoimmunotherapy (ISPI), provides an alternative to traditional therapies for melanoma patients with cutaneous metastases. A 6-week cycle of ISPI is carried out on cutaneous metastases located in a designated 20 x 20 cm treatment area: 2 weeks of pretreatment with twice-daily topical applications of imiquimod (5% cream under plastic occlusion), with a laser treatment session at week 2 and again at week 4. Topical imiquimod is continued for the entire 6-week cycle. Two patients with late-stage melanoma were treated with ISPI. Patient 1 had the primary tumour and local metastases on the left arm, as well as metastatic tumours in the lungs [American Joint Committee on Cancer (AJCC) stage IV]. Patient 2 had a head and neck melanoma with multiple local metastases (AJCC stage IIIC), which had failed repeated attempts at surgical resection and high-dose radiation therapy. Patient 1 is now free of all clinically detectable tumours (including the lung metastases) >20 months after the first treatment cycle. Patient 2 has been free of any clinical evidence of the tumour for over 6 months. These two cases demonstrate that ISPI can clear local tumour and trigger beneficial systemic responses, with a side-effect profile that compares favourably with other treatments for advanced melanoma.lld:pubmed
pubmed-article:17107404pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17107404pubmed:languageenglld:pubmed
pubmed-article:17107404pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17107404pubmed:citationSubsetIMlld:pubmed
pubmed-article:17107404pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17107404pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17107404pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17107404pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17107404pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17107404pubmed:statusMEDLINElld:pubmed
pubmed-article:17107404pubmed:monthDeclld:pubmed
pubmed-article:17107404pubmed:issn0007-0963lld:pubmed
pubmed-article:17107404pubmed:authorpubmed-author:NordquistR...lld:pubmed
pubmed-article:17107404pubmed:authorpubmed-author:PerryL ALAlld:pubmed
pubmed-article:17107404pubmed:authorpubmed-author:ChenW RWRlld:pubmed
pubmed-article:17107404pubmed:authorpubmed-author:TeagueT KTKlld:pubmed
pubmed-article:17107404pubmed:authorpubmed-author:NaylorM FMFlld:pubmed
pubmed-article:17107404pubmed:issnTypePrintlld:pubmed
pubmed-article:17107404pubmed:volume155lld:pubmed
pubmed-article:17107404pubmed:ownerNLMlld:pubmed
pubmed-article:17107404pubmed:authorsCompleteYlld:pubmed
pubmed-article:17107404pubmed:pagination1287-92lld:pubmed
pubmed-article:17107404pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:17107404pubmed:meshHeadingpubmed-meshheading:17107404...lld:pubmed
pubmed-article:17107404pubmed:meshHeadingpubmed-meshheading:17107404...lld:pubmed
pubmed-article:17107404pubmed:meshHeadingpubmed-meshheading:17107404...lld:pubmed
pubmed-article:17107404pubmed:meshHeadingpubmed-meshheading:17107404...lld:pubmed
pubmed-article:17107404pubmed:meshHeadingpubmed-meshheading:17107404...lld:pubmed
pubmed-article:17107404pubmed:meshHeadingpubmed-meshheading:17107404...lld:pubmed
pubmed-article:17107404pubmed:meshHeadingpubmed-meshheading:17107404...lld:pubmed
pubmed-article:17107404pubmed:meshHeadingpubmed-meshheading:17107404...lld:pubmed
pubmed-article:17107404pubmed:meshHeadingpubmed-meshheading:17107404...lld:pubmed
pubmed-article:17107404pubmed:meshHeadingpubmed-meshheading:17107404...lld:pubmed
pubmed-article:17107404pubmed:meshHeadingpubmed-meshheading:17107404...lld:pubmed
pubmed-article:17107404pubmed:meshHeadingpubmed-meshheading:17107404...lld:pubmed
pubmed-article:17107404pubmed:meshHeadingpubmed-meshheading:17107404...lld:pubmed
pubmed-article:17107404pubmed:meshHeadingpubmed-meshheading:17107404...lld:pubmed
pubmed-article:17107404pubmed:meshHeadingpubmed-meshheading:17107404...lld:pubmed
pubmed-article:17107404pubmed:meshHeadingpubmed-meshheading:17107404...lld:pubmed
pubmed-article:17107404pubmed:meshHeadingpubmed-meshheading:17107404...lld:pubmed
pubmed-article:17107404pubmed:year2006lld:pubmed
pubmed-article:17107404pubmed:articleTitleIn situ photoimmunotherapy: a tumour-directed treatment for melanoma.lld:pubmed
pubmed-article:17107404pubmed:affiliationDepartment of Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA. marknaylor@earthlink.netlld:pubmed
pubmed-article:17107404pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17107404pubmed:publicationTypeCase Reportslld:pubmed
pubmed-article:17107404pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:17107404pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17107404lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17107404lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17107404lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17107404lld:pubmed